Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests
The DOI matches its Crossref record.
Abstract
To the Editor: During routine serum protein electrophoresis (SPE), we recently detected an apparent IgG heavy-chain immunoglobulin in a 51-year-old woman with a 5-year history of IgDκ multiple myeloma. Other relevant laboratory values at the time included the following: serum creatinine, 159 μmol/L (reference interval, 62–97 μmol/L); IgG, 2.55 g/L (reference interval, 6.00–17.00 g/L); IgM, <0.25 g/L (reference interval, 0.35–2.90 g/L); and IgA, 0.40 g/L (reference interval, 0.40–4.00 g/L). The rarity of an IgG heavy-chain gammopathy in combination with an IgDκ and a low quantitative IgG value raised suspicion of an interference. Consultation with the treating physician revealed that the patient was enrolled in a phase II clinical trial of dexamethasone and siltuximab for the treatment of refractory myeloma. Siltuximab (Centocor), a high-affinity antibody to human interleukin-6, is currently being used in clinical trials for the treatment of a number of malignancies, including multiple myeloma. Siltuximab is a chimeric immunoglobulin comprising the variable antigen-binding region of a mouse antibody and the constant region of human IgG1κ (1). It binds to human interleukin-6, a survival factor for myeloma cells (2). We obtained siltuximab from the manufacturer …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Siltuximab (CNTO 328): a promising option for human malignancies
Chen, B.-A., & Chen, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86438 · Cited by 65
“9 In this review, we mainly focus on addressing the mechanisms of siltuximab.”
Metadata
- Authors
- McCudden, C. R., Voorhees, P. M., Hainsworth, S. A., Whinna, H. C., Chapman, J. F., Hammett-Stabler, C. A., & Willis, M. S.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-01
- Volume
- 56
- Issue
- 12
- Pages
- 1897-1899
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2125210373
- Cited by
- 77
- References
- 0
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests. https://app.cochat.ai/papers/10.1373/clinchem.2010.152116
- The paper
- McCudden, C. R., Voorhees, P. M., Hainsworth, S. A., Whinna, H. C., Chapman, J. F., Hammett-Stabler, C. A., & Willis, M. S. (2010). Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests. Clinical Chemistry. https://doi.org/10.1373/clinchem.2010.152116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.